Investors in Mayne Pharma are increasingly calling for a break-up of the company as its shares continue to underperform, according to reports from the Australian Financial Review.
The push for a structural change comes as the stock languishes in what has been described as a graveyard of unloved equities, with shareholders looking for a way to unlock value after a prolonged period of stagnation.
The current sentiment marks a sharp contrast to the high-stakes drama of 2025, when Mayne Pharma was the center of a contentious takeover battle.
That episode featured a dramatic intervention by the Australian Treasurer, intense maneuvering at the Takeovers Panel, and significant debate over the application of material adverse change clauses.
Despite the intense scrutiny and regulatory involvement, the acquisition did not proceed, leaving the company and its investors in a state of limbo.
With the takeover hopes dashed, the focus has shifted to internal restructuring.